A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients

NCT03343145 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Leucostim 5µg/kg/day
BIOLOGICAL: Neupogen 5µg/kg/day

Sponsor

Dong-A ST Co., Ltd.